Corrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Human Pathology (2016) 57 (116–125)(S0046817716301605)(10.1016/j.humpath.2016.07.008));Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma

Human Pathology

Volumn 57, Issue , 2016, Pages 116-125

  Weiss, Sarah A ^a   Han, Sung Won ^a,b   Lui, Kevin ^a,c   Tchack, Jeremy ^a   Shapiro, Richard ^a   Berman, Russell ^a   Zhong, Judy ^a   Krogsgaard, Michelle ^a   Osman, Iman ^a   Darvishian, Farbod ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Korea University   (South Korea)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Brisk; Host immune response; Melanoma; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; EOSIN; HEMATOXYLIN; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PTPRC PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE BIOPSY; SKIN ULCER; T LYMPHOCYTE ACTIVATION; UPREGULATION; AGED; CANCER GRADING; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; SKIN NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

AGED; ANTIGENS, CD3; ANTIGENS, CD45; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; NEOPLASM GRADING; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84984823911     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2017.03.001     Document Type: Erratum

References (33)

1. [1] Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2015. CA Cancer J Clin 65 (2015), 5–29.
2. [2] Balch, CM, Buzaid, AC, Atkins, MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88 (2000), 1484–1491.
3. [3] Balch, CM, Buzaid, AC, Soong, SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001), 3635–3648.
4. [4] Balch, CM, Gershenwald, JE, Soong, SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27 (2009), 6199–6206.
5. [5] Balch, CM, Gershenwald, JE, Soong, SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28 (2010), 2452–2459.
6. [6] Balch, CM, Soong, SJ, Gershenwald, JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001), 3622–3634.
7. [7] American Cancer Society, What are the survival rates for melanoma skin cancer, by stage?. Available at: http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates [accessed 11.11.15].
8. [8] Ropponen, KM, Eskelinen, MJ, Lipponen, PK, Alhava, E, Kosma, VM, Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182 (1997), 318–324.
9. [9] Hwang, WT, Adams, SF, Tahirovic, E, Hagemann, IS, Coukos, G, Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 124 (2012), 192–198.
10. [10] Adams, S, Gray, RJ, Demaria, S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32 (2014), 2959–2966.
11. [11] Azimi, F, Scolyer, RA, Rumcheva, P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30 (2012), 2678–2683.
12. [12] Clark, WH Jr., Elder, DE, Guerry, D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81 (1989), 1893–1904.
13. [13] Barnhill, RL, Fine, JA, Roush, GC, Berwick, M, Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78 (1996), 427–432.
14. [14] Tuthill, RJ, Unger, JM, Liu, PY, Flaherty, LE, Sondak, VK, Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 118 (2002), 504–511.
15. [15] Taylor, RC, Patel, A, Panageas, KS, Busam, KJ, Brady, MS, Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25 (2007), 869–875.
16. [16] Burton, AL, Roach, BA, Mays, MP, et al. Prognostic significance of tumor-infiltrating lymphocytes in melanoma. Am Surg 77 (2011), 188–192.
17. [17] Mandala, M, Imberti, GL, Piazzalunga, D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer 45 (2009), 2537–2545.
18. [18] Thomas, NE, Busam, KJ, From, L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol 31 (2013), 4252–4259.
19. [19] Clemente, CG, Mihm, MC Jr., Bufalino, R, Zurrida, S, Collini, P, Cascinelli, N, Prognostic value of tumor-infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996), 1303–1310.
20. [20] Qiagen, Purification of total RNA from FFPE cores using the RNeasy FFPE kit., 2011 Available at: https://www.qiagen.com/us/resources/resourcedetail?id=665fc085-8691-4fcd-a458-a47c9be312db&lang=en [accessed 11.11.15].
21. [21] Nanostring Technologies gene expression analysis protocol. Available at: www.nanostring.com [accessed 11.11.15].
22. [22] Qiagen, Integrative Pathway Analysis. Available at: http://www.ingenuity.com/products/ipa [accessed 11.11.15].
23. [23] Rao, UN, Lee, SJ, Luo, W, Mihm, MC Jr., Kirkwood, JM, Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol 133 (2010), 646–653.
24. [24] Gerber, AL, Munst, A, Schlapbach, C, et al. High expression of FOXP3 in primary melanoma is associated with tumour progression. Br J Dermatol 170 (2014), 103–109.
25. [25] Ladanyi, A, Mohos, A, Somlai, B, et al. FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol Oncol Res 16 (2010), 303–309.
26. [26] Ladanyi, A, Kiss, J, Mohos, A, et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 60 (2011), 1729–1738.
27. [27] Miracco, C, Mourmouras, V, Biagioli, M, et al. Utility of tumour-infiltrating CD25 + FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 18 (2007), 1115–1122.
28. [28] Piras, F, Colombari, R, Minerba, L, et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104 (2005), 1246–1254.
29. [29] Erdag, G, Schaefer, JT, Smolkin, ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72 (2012), 1070–1080.
30. [30] Wang, H, Kadlecek, TA, Au-Yeung, BB, et al. ZAP-70: an essential kinase in T-cell signaling. Cold Spring Harb Perspect Biol, 2, 2010, a002279.
31. [31] Genomic classification of cutaneous melanoma. Cell, 161, 2015, 1681–1696.
32. [32] Capone, M, Immunoscore: a new possible approach for melanoma classification. J Immunother Cancer, 2(Suppl. 3), 2014, 193.
33. [33] Galon, J, Pages, F, Marincola, FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med, 10, 2012, 205.